Holen Sie sich die Stockscreener-App
1.93
2.12%
0.04
Handel nachbörslich:
1.95
0.02
+1.04%
Schlusskurs vom Vortag:
$1.89
Offen:
$1.89
24-Stunden-Volumen:
3.10M
Relative Volume:
0.71
Marktkapitalisierung:
$323.51M
Einnahmen:
$250.00K
Nettoeinkommen (Verlust:
$-16.78M
KGV:
-1.2998
EPS:
-1.4848
Netto-Cashflow:
$-10.85M
1W Leistung:
+8.43%
1M Leistung:
+18.40%
6M Leistung:
+1.31%
1J Leistung:
+170.08%
1-Tages-Spanne:
$1.87
$2.02
1-Wochen-Bereich:
$1.48
$2.02
52-Wochen-Spanne:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Firmenname
Palisade Bio Inc
Sektor
Branche
Telefon
(858) 704-4900
Adresse
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.93 | 316.81M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-09 | Eingeleitet | B. Riley Securities | Buy |
| 2025-12-29 | Eingeleitet | Piper Sandler | Overweight |
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN
Palisade Bio partners with Iterative Health to advance PALI-2108 - tipranks.com
Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - investing.com
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
Palisade Bio, Inc. (PALI) stock price, news, quote and history - Yahoo Finance UK
Clear Street Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail
Clear Street reiterates Palisade Bio stock rating on trial data By Investing.com - Investing.com South Africa
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - moomoo.com
Clear Street reiterates Palisade Bio stock rating on trial data - Investing.com
Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - marketscreener.com
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals - MarketBeat
Support Test: Can Palisade Bio Inc beat the S P 500Market Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Palisade Bio posts trial data for lead asset (PALI:NASDAQ) - Seeking Alpha
Crafting a New Financial Era: Palisade Bio Inc.’s Strategic Moves - StocksToTrade
Palisade Bio stock maintains buy rating at Stifel on trial data - Investing.com Canada
Palisade Bio stock maintains buy rating at Stifel on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - moomoo.com
Palisade Bio reports Phase 1b trial results for Crohn’s drug By Investing.com - Investing.com South Africa
Palisade Bio reports Phase 1b trial results for Crohn’s drug - investing.com
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease - globenewswire.com
HC Wainwright Forecasts Palisade Bio Q1 Earnings - MarketBeat
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PALI Should I Buy - Intellectia AI
HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI) - marketbeat.com
Big Picture: Can Palisade Bio Inc expand its profit marginsMarket Performance Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating - Seeking Alpha
Palisade Bio 2026 10-K: Clinical Development, Risk Factors, and Precision Medicine Strategies for IBD - Minichart
Aug Spikes: Can Palisade Bio Inc expand its profit marginsQuarterly Earnings Report & Weekly Return Optimization Alerts - baoquankhu1.vn
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS - MarketBeat
Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Palisade Bio 10-K: Net loss $16.8M, EPS $(0.30) - TradingView
[10-K] PALISADE BIO, INC. Files An... - Stock Titan
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients - Insider Monkey
PALI Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Day Trade: Can Palisade Bio Inc beat the S P 500Bear Alert & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (PALI) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Palisade Bio (PALI) Stock Analysis Report | Financials & Insights - Benzinga Japan
RSI Check: Will Palisade Bio Inc outperform its industry peers2026 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Macro: Can Palisade Bio Inc maintain sales growth2025 Buyback Activity & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-03-07 13:46:23 - baoquankhu1.vn
US Market Recap: Will Palisade Bio Inc stock recover after earningsTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
PALI Earnings History & Surprises | EPS & Revenue Results | PALISADE BIO INC (NASDAQ:PALI) - ChartMill
Treasury Yields: Will Palisade Bio Inc benefit from current market trends2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
Finanzdaten der Palisade Bio Inc-Aktie (PALI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Palisade Bio Inc-Aktie (PALI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):